GMP cell therapy consumables market seen reaching $73.96 billion by 2030

The Business Research Company says the GMP cell therapy consumables market is growing fast as cell therapies move deeper into clinical use, manufacturing scale-up and regulatory oversight. The market is projected to rise from $22.73 billion in 2025 to $73.96 billion by 2030, with North America leading and Asia-Pacific expected to grow fastest.

Why it matters: - GMP cell therapy consumables support the manufacturing of cell-based treatments used in gene therapy, vaccine development, tissue engineering, toxicity testing and pharmaceutical research. - Rapid market growth points to rising demand for scalable, compliant inputs as cell therapies move from research into broader commercialization. - Chronic disease growth is expanding the need for advanced therapies and the consumables used to produce them.

What happened: - The Business Research Company released a report on the GMP cell therapy consumables market on August 7, 2026. - The report estimates the market will grow from $22.73 billion in 2025 to $28.79 billion in 2026. - The report projects the market will reach $73.96 billion by 2030. - The report puts the market’s 2025-2026 growth rate at 26.7% and its 2026-2030 CAGR at 26.6%. - The company made a free sample available here. - The full report is available here.

The details: - The report ties recent growth to more clinical trials in cell therapy, expanding regenerative medicine research, wider use of GMP manufacturing protocols, higher investment in cell-based therapies and more advanced cell culture tools. - The forecast is driven by commercialization of cell therapy products, demand for scalable GMP manufacturing, growth in gene therapy and immunotherapy pipelines, more process automation and tighter regulatory oversight. - The report highlights stronger demand for GMP-compliant consumables, broader use of single-use bioprocessing equipment, more automated cell processing, standardization of cell culture solutions and greater focus on quality and regulatory adherence. - The report defines GMP cell therapy consumables as products and materials made under Good Manufacturing Practices for cell-based therapeutic applications. - North America was the largest regional market in 2025. - Asia-Pacific is expected to be the fastest-growing region during the forecast period. - The report also covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - The market analysis package includes market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspot infographics, key technology and future trend analysis, and updated graphics and tables.

Between the lines: - The report suggests cell therapy supply chains are shifting from early-stage research support toward industrial-scale, quality-controlled production. - Rising chronic disease prevalence strengthens the business case for cell therapies, which in turn increases demand for GMP-grade inputs. - The regional split points to established demand in North America and faster manufacturing expansion in Asia-Pacific. - In June 2024, the UK National Health Service said 3,615,330 people diagnosed with non-diabetic hyperglycemia or pre-diabetes were registered with general practitioners in 2023, up 18% from 3,065,825 in 2022.

What's next: - The report expects continued fast growth through 2030 as more cell therapy products commercialize and manufacturing scales. - The company says automation, standardization and regulatory compliance will become more important across the market. - The report’s publication package is aimed at buyers looking for forecasting tools and regional market breakdowns.

The bottom line: - GMP cell therapy consumables are moving from a niche research input to a core part of the cell therapy manufacturing stack, with demand expected to keep climbing through the end of the decade.